All News

RheumNow Podcast square

RheumNow Podcast – Quackademia (10.15.2021)

Jack Cush, MD

Dr. Jack Cush reviews the FDA approvals, news and the latest journal articles from the past week on RheumNow.com.

Read Article
FDA,approved,stamp,blue

FDA Approves Avacopan for ANCA-Associated Vasculitis

Jack Cush, MD

October 8, 2021 the U.S.

Read Article
RheumNow Podcast square

RheumNow Podcast – I Wanna New Drug.V2 (9.24.2021)

Jack Cush, MD

Almost three years ago to the day, I did a podcast entitled, "I wanna new drug." As I go over this week's podcast, I want to say it again. I want a new drug safe enough to use during pregnancy, for PMR, for GVHD, and more. I'm going to cover these, and other topics including lupus, COVID breakthrough infections, and statin use and the risk of RA, as I review the news and journal articles from the past week on RheumNow.

Read Article
colitis.jpg

TNF Inhibitor Induced IgA Vasculitis in IBD

Jack Cush, MD

A new descriptive series shows an uncommon association between IgA vasculitis (IgAV) and inflammatory bowel diseases (IBD), with most cases interestingly arising after  or during anti-TNF-α therapy.

Read Article
RheumNow Podcast square

RheumNow Podcast – Booster Shots for COVID (8.13.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
vasculitis.Churg-Strauss_syndrome.wikipedia.jpg

Mepolizumab Dosing in Eosinophilic Granulomatosis with Polyangiitis

Jack Cush, MD

A new European real world experience study shows that mepolizumab is effective at both 100 or 300mg every 4 weeks in patients with the rarely encountered eosinophilic granulomatosis with polyangiitis (EGPA; or Churg-Strauss Syndrome). 

Read Article
RheumNow Podcast square

RheumNow Podcast – Saphnelo (Anifrolumab) Approved for Lupus (8.6.2021)

Jack Cush, MD

It was a banner week at the FDA; a new drug approval you should know about; a lot of information about pregnancy and safety; and an interesting case plus a question from one of our readers submitted via Back Talk. This and more in this week's podcast. Let's dive in.

Read Article
83 patients w/ ANCA Assoc. Vasculitis, hospital admited, 44 died in-ICU (53%) w/ death by infection (61%), active vasculitis (34%). Predictors of ICU death were APACHE II score (OR=1.3) and respiratory failure (OR=620). https://t.co/ZPBkVWy40I

Links:

Dr. John Cush RheumNow ( View Tweet)

In case you missed it: FDA Approves Avacopan for ANCA-Associated Vasculitis https://t.co/L7UwhYBaVY #RheumNow https://t.co/HypjLMLwjU

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves Avacopan for ANCA-Associated Vasculitis https://t.co/L7UwhYBaVY #RheumNow https://t.co/0cGN5eyfCl

Links:

Dr. John Cush RheumNow ( View Tweet)
Encouraging DBRPCT of Rituximab in #PMR: 116 screened, 49 enrolled, 47 completed: 23 on RTX vs 24 on PBO. Steroid-free remission at 21 wks seen with 11/23 (48%) RTX pts vs 5/24 (21%) on PBO (p=0·049). Infusion Rxns: 10 RTX vs 3 PBO); 1 SAE (PE) on RTX https://t.co/U2ZGNrpi0i

Links:

Dr. John Cush RheumNow ( View Tweet)

The EMA has recommended Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA) https://t.co/0aVoDpaTPT

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of long-term steroid (GC) in PMR (24 studies) 77%, 51%, & 25% PMR pts still GC respectively 1, 2, & 5 yrs. 1st Yr pooled relapse rate =43%. Prolonged GC use/relapse moreso in Females, Hi ESR, periph arthritis, starting dose, tapering speed https://t.co/n0gGlik1hO https://t.co/WBqdfUW2RS

Links:

Dr. John Cush RheumNow ( View Tweet)
Cochrane review finds only 2 studies showing tocilizumab to be beneficial in GCA (sustained remission, relapse-free survival, need for escape therapy). https://t.co/sQjIBAiWKN

Links:

Dr. John Cush RheumNow ( View Tweet)

Article in press: Can ANCA titers predict relapse in patients with GPA? Cohort study by @UofT_DoM - microscopic hematuria and MPO ab at month 12 predicted increased risk of relapse https://t.co/ks3Gj5iSLR

Links:

Seminars in Arthritis and Rheumatism seminarthrheum ( View Tweet)

ICYMI: One of our top June videos WATCH: Is blindness with Tocilizumab in GCA a worry? Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021 https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w0IGAx

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: EULAR guidelines rec starting prednisone dose in #PMR to be between 12.5-25mg/d. A cross sectional study of 138 pts (63M, 75F, age 73.4 yes) saw the mean starting dose to be 19.2±7.7 mg.  https://t.co/Yf3yqRRMCK

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/sJpbzIbBJt

Links:

Dr. John Cush RheumNow ( View Tweet)
While myeloperoxidase (MPO) Abs are seen in idiopathic pulmonary fibrosis (IPF), only 7–23% develop vasculitis. Study of 58 pts w/ IPF & MPO Abs - UIP most frequent ILD pattern, 13 had rheumatic dz; MPO Abs did not change survival of UIP/IPF pts https://t.co/RXXIPUBMBT https://t.co/v3KhEaefZD

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×